CD8A and cancer: We showed that genetic KO and pharmacological inhibition of Cbl-b prevents Notch1 degradation in response to adenosine and reactivates its signaling, thus resulting in enhanced CD8+ T-cell effector functions, anti-cancer response and resistance to immunosuppression.